Baxter, J.S.,
Johnson, N.,
Tomczyk, K,
Gillespie, A.,
Maguire, S.,
Brough, R.,
Fachal, L,
Michailidou, K.,
Bolla, M.K.,
Wang, Q.,
Dennis, J.,
Ahearn, T.U.,
Bermisheva, M. (2021) of
estrogen receptor-positive breast cancer (odds ratio = 0.77, 95% CI 0.74–0.81, p = 3.1 × 10−31). © 2021
Dorling, L.,
Carvalho, S.,
Allen, J.,
González-Neira, A.,
Luccarini, C.,
Wahlström, C.,
Pooley, K.A.,
Parsons, M.T.,
Fortuno, C.,
Wang, Q.,
Bolla, M.K.,
Dennis, J.,
Bermisheva, M.,
Khusnutdinova, E.,
Prokofyeva, D.,
other additional authors (2021) .0. For protein-truncating variants in ATM and CHEK2, odds ratios were higher for
estrogen receptor (ER
Khairullina, V.R.,
Taipov, I.A.,
Gerchikov, A.Y.,
Vasil'ev, M.N.,
Zarudii, F.S.,
Boegel, H. (2014) and BLT2
receptors were identified and the extents of their influences on the target property were
Kochetova, OV,
Avzaletdinova, DS,
Shangareeva, ZA,
Akhmadishina, LZ,
Korytina, GF,
Victorov, VV,
Victorova, TV (2021) polymorphic variants of genes coding for glutamate
receptors (GRIK5 rs8099939, GRIK3 rs534131, GRIA1 rs2195450